---
title: "Atara Biotherapeutics, Inc. (ATRA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ATRA.US.md"
symbol: "ATRA.US"
name: "Atara Biotherapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-03-13T00:14:51.621Z"
locales:
  - [en](https://longbridge.com/en/quote/ATRA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ATRA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ATRA.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/ATRA.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/ATRA.US.md)


# Atara Biotherapeutics, Inc. (ATRA.US)

## Company Overview

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.atarabio.com](https://www.atarabio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-12T04:30:14.000Z

**Overall: C (0.44)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 158 / 406 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 51.27% |  |
| Net Profit YoY | 117.57% |  |
| P/B Ratio | -1.23 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 44919764.05 |  |
| Revenue | 151930000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -36.80% | E |
| Profit Margin | 15.40% | A |
| Gross Margin | 12.40% | D |
| Revenue YoY | 51.27% | A |
| Net Profit YoY | 117.57% | A |
| Total Assets YoY | -78.86% | E |
| Net Assets YoY | 59.54% | A |
| Cash Flow Margin | 649.25% | C |
| OCF YoY | 51.27% | A |
| Turnover | 1.76 | A |
| Gearing Ratio | 221.44% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Atara Biotherapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "51.27%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "117.57%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-1.23",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "44919764.05",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "151930000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-36.80%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "15.40%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "12.40%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "51.27%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "117.57%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-78.86%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "59.54%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "649.25%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "51.27%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "1.76",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "221.44%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 1.92 | 6/406 | 16.74 | 5.48 | 1.61 |
| PB | -1.23 | 489/406 | - | - | - |
| PS (TTM) | 0.30 | 6/406 | 0.57 | 0.34 | 0.24 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-09T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 33% |
| Hold | 1 | 33% |
| Sell | 1 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.90 |
| Highest Target | 6.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ATRA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ATRA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ATRA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ATRA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**